Cargando…

Oridonin Sensitizes Hepatocellular Carcinoma to the Anticancer Effect of Sorafenib by Targeting the Akt Pathway

BACKGROUND: Oridonin is the core bioactive component of Rabdosia rubescens, a traditional Chinese herbal medicine used in the treatment of hepatoma. Sorafenib, a targeted therapeutic agent for advanced hepatocellular carcinoma (HCC), has recently been shown to exert limited clinical effects. However...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Xuguang, Chen, Weirun, Liu, Kaihang, Zhang, Sheng, Yang, Ru, Liu, Kairui, Li, Dateng, Huang, Youxing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7494228/ https://www.ncbi.nlm.nih.gov/pubmed/32982405 http://dx.doi.org/10.2147/CMAR.S257482

Ejemplares similares

Bisdemethoxycurcumin Inhibits Hepatocellular Carcinoma Proliferation Through Akt Inactivation via CYLD-Mediated Deubiquitination
por: Qiu, Chengjiang, et al.
Publicado: (2020)

Oridonin Sensitizes Hepatocellular Carcinoma to the Anticancer Effect of Sorafenib by Targeting the Akt Pathway [Corrigendum]
Publicado: (2021)

Oridonin Delays Aging Through the AKT Signaling Pathway
por: An, Yongpan, et al.
Publicado: (2022)

Inhibition of MMP-2 Expression Enhances the Antitumor Effect of Sorafenib in Hepatocellular Carcinoma by Suppressing the PI3K/AKT/mTOR Pathway
por: Tan, Wenliang, et al.
Publicado: (2017)

Design and synthesis of novel oridonin analogues as potent anticancer agents
por: Shen, Qing-Kun, et al.
Publicado: (2018)

Recent advances in oridonin derivatives with anticancer activity
por: Sobral, Pedro J. M., et al.
Publicado: (2023)

Oridonin inhibits aberrant AKT activation in breast cancer
por: Sun, Bowen, et al.
Publicado: (2018)

Camptothecin improves sorafenib sensitivity by inhibiting Nrf2‑ARE pathway in hepatocellular carcinoma
por: Sun, Liwei, et al.
Publicado: (2023)

Oridonin induces the apoptosis of metastatic hepatocellular carcinoma cells via a mitochondrial pathway
por: ZHU, MIN, et al.
Publicado: (2013)

SENP2 Reduces Hepatocellular Carcinoma Stemness and Improves Sorafenib Sensitivity Through Inactivating the AKT/GSK3β/CTNNB1 Pathway
por: Tang, Xiaohui, et al.
Publicado: (2021)

Oridonin Alleviates IRI-Induced Kidney Injury by Inhibiting Inflammatory Response of Macrophages via AKT-Related Pathways
por: Yan, Ying, et al.
Publicado: (2020)

Knockdown of AKR1C3 Promoted Sorafenib Sensitivity Through Inhibiting the Phosphorylation of AKT in Hepatocellular Carcinoma
por: Zheng, Jia, et al.
Publicado: (2022)

Oridonin exerts anticancer effect on osteosarcoma by activating PPAR-γ and inhibiting Nrf2 pathway
por: Lu, Ying, et al.
Publicado: (2018)

Antiangiogenic effects of oridonin
por: Tian, Lili, et al.
Publicado: (2017)

Therapeutic Potential of Oridonin and Its Analogs: From Anticancer and Antiinflammation to Neuroprotection
por: Xu, Jimin, et al.
Publicado: (2018)

BEZ235 Increases the Sensitivity of Hepatocellular Carcinoma to Sorafenib by Inhibiting PI3K/AKT/mTOR and Inducing Autophagy
por: Cao, Weiya, et al.
Publicado: (2021)

Oridonin inhibits epithelial-mesenchymal transition of human nasopharyngeal carcinoma cells by negatively regulating AKT/STAT3 signaling pathway
por: Liu, Wei, et al.
Publicado: (2021)

Preliminary safety assessment of oridonin in zebrafish
por: Tian, Lili, et al.
Publicado: (2019)

Hypoxia-Induced Aquaporin-3 Changes Hepatocellular Carcinoma Cell Sensitivity to Sorafenib by Activating the PI3K/Akt Signaling Pathway
por: Malale, Kija, et al.
Publicado: (2020)

Bilirubin inhibits the anticancer activity of sorafenib by blocking MCL-1 degradation in hepatocellular carcinoma cells
por: Yao, Leyi, et al.
Publicado: (2022)

Influence of verapamil on the pharmacokinetics of oridonin in rats
por: Liu, Jing, et al.
Publicado: (2019)

IGF-1R down regulates the sensitivity of hepatocellular carcinoma to sorafenib through the PI3K / akt and RAS / raf / ERK signaling pathways
por: Cai, Wenpeng, et al.
Publicado: (2023)

Oridonin Sensitizes Cisplatin-Induced Apoptosis via AMPK/Akt/mTOR-Dependent Autophagosome Accumulation in A549 Cells
por: Yang, Huahong, et al.
Publicado: (2019)

Oridonin synergistically enhances JQ1-triggered apoptosis in hepatocellular cancer cells through mitochondrial pathway
por: Zhang, Hua-Peng, et al.
Publicado: (2017)

Oridonin prevents insulin resistance–mediated cognitive disorder through PTEN/Akt pathway and autophagy in minimal hepatic encephalopathy
por: Wen, Fangfang, et al.
Publicado: (2019)

Hypoxia-Induced Aquaporin-3 Changes Hepatocellular Carcinoma Cell Sensitivity to Sorafenib by Activating the PI3K/Akt Signaling Pathway [Retraction]
Publicado: (2021)

Y-box binding protein 1 augments sorafenib resistance via the PI3K/Akt signaling pathway in hepatocellular carcinoma
por: Liu, Ting, et al.
Publicado: (2021)

BCRP/ABCG2 Inhibition Sensitizes Hepatocellular Carcinoma Cells to Sorafenib
por: Huang, Wei-Chien, et al.
Publicado: (2013)

Melatonin Increases the Sensitivity of Hepatocellular Carcinoma to Sorafenib through the PERK-ATF4-Beclin1 Pathway
por: Zhou, Bei, et al.
Publicado: (2019)

The kynurenine derivative 3-HAA sensitizes hepatocellular carcinoma to sorafenib by upregulating phosphatases
por: Gan, Guifang, et al.
Publicado: (2021)

MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway
por: He, Changjun, et al.
Publicado: (2015)

Zirconium-Porphyrin PCN-222: pH-responsive Controlled Anticancer Drug Oridonin
por: Leng, Xin, et al.
Publicado: (2018)

Oridonin impedes breast cancer growth by blocking cells in S phase and inhibiting the PI3K/AKT/mTOR signaling pathway
por: Zhang, Weijie, et al.
Publicado: (2023)

Sorafenib inhibits macrophage-mediated epithelial-mesenchymal transition in hepatocellular carcinoma
por: Deng, Yan-Ru, et al.
Publicado: (2016)

Potential Treatment Strategies for Hepatocellular Carcinoma Cell Sensitization to Sorafenib
por: Jiang, Zhonghao, et al.
Publicado: (2023)

Selective synergistic anticancer effects of cisplatin and oridonin against human p53-mutant esophageal squamous carcinoma cells
por: Yang, Huiyu, et al.
Publicado: (2021)

FNDC5 Causes Resistance to Sorafenib by Activating the PI3K/Akt/Nrf2 Pathway in Hepatocellular Carcinoma Cells
por: Liu, Huayuan, et al.
Publicado: (2022)

LncRNA SNHG1 contributes to sorafenib resistance by activating the Akt pathway and is positively regulated by miR-21 in hepatocellular carcinoma cells
por: Li, Weidong, et al.
Publicado: (2019)

Sestrin 2 confers primary resistance to sorafenib by simultaneously activating AKT and AMPK in hepatocellular carcinoma
por: Dai, Jimin, et al.
Publicado: (2018)

Sorafenib modulates the radio sensitivity of hepatocellular carcinoma cells in vitro in a schedule-dependent manner
por: Li, Qiaoqiao, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_3m3n1tq5vuthj5q59fltbk9cac